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Background. Single-nucleotide polymorphisms (SNPs) in immune genes have been associated with susceptibility to
invasive mold infection (IMI) among hematopoietic stem cell but not solid-organ transplant (SOT) recipients.
Methods. Twenty-four SNPs from systematically selected genes were genotyped among 1101 SOT recipients
(715 kidney transplant recipients, 190 liver transplant recipients, 102 lung transplant recipients, 79 heart transplant
recipients, and 15 recipients of other transplants) from the Swiss Transplant Cohort Study. Association between
SNPs and the end point were assessed by log-rank test and Cox regression models. Cytokine production upon As-
pergillus stimulation was measured by enzyme-linked immunosorbent assay in peripheral blood mononuclear cells
(PBMCs) from healthy volunteers and correlated with relevant genotypes.
Results. Mold colonization (n = 45) and proven/probable IMI (n = 26) were associated with polymorphisms in
the genes encoding interleukin 1β (IL1B; rs16944; recessive mode, P = .001 for colonization and P = .00005 for
IMI, by the log-rank test), interleukin 1 receptor antagonist (IL1RN; rs419598; P = .01 and P = .02, respectively), and
β-defensin 1 (DEFB1; rs1800972; P = .001 and P = .0002, respectively). The associations with IL1B and DEFB1 re-
mained signiﬁcant in a multivariate regression model (P = .002 for IL1B rs16944; P = .01 for DEFB1 rs1800972). The
presence of 2 copies of the rare allele of rs16944 or rs419598 was associated with reduced Aspergillus-induced inter-
leukin 1β and tumor necrosis factor α secretion by PBMCs.
Conclusions. Functional polymorphisms in IL1B and DEFB1 inﬂuence susceptibility to mold infection in SOT
recipients. This observation may contribute to individual risk stratiﬁcation.
Keywords. innate immunity; single nucleotide polymorphism; genetic susceptibility; aspergillosis; invasive mold
infections; solid organ transplant; interleukin-1 beta.
Over 100 000 solid-organ transplantations (SOTs) are
performed worldwide each year [1]. Despite recent im-
provements in the management of SOT recipients, in-
fectious complications after transplantation remain a
challenging issue [2]. In particular invasive aspergillosis
can occur in up to 3% of SOT recipients and is associ-
ated with a mortality rates of 20%–76% [3, 4]. Risk
factors for the development of invasive aspergillosis in-
clude type and level of immunosuppression, use of renal
replacement therapy, older age, and cytomegalovirus
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(CMV) disease [3, 5]. However, not all patients with these risk
factors develop invasive mold infections (IMIs), while some pa-
tients without these risk factors do, making it difﬁcult to predict
the individual-level risk of developing IMI.
Over the last decade, a series of studies have identiﬁed com-
mon genetic polymorphisms that are associated with the devel-
opment of invasive aspergillosis among hematopoietic stem
cell transplant recipients and other patients with onco-
hematological conditions [6, 7]. The identiﬁcation of speciﬁc
genetic variants may improve individual risk stratiﬁcation
and allow the development of personalized management strat-
egies, as well as the use of prophylaxis or speciﬁc surveillance in
individuals at high risk to develop invasive aspergillosis [6]. To
date, no studies examined the role of such genetic poly-
morphisms on the susceptibility to fungal infections among
SOT recipients. To our knowledge, this study is the ﬁrst to ex-
plore the role of host genetics in susceptibility to IMI in SOT
recipients.
MATERIALS AND METHODS
Patients and Study Design
The Swiss Transplant Cohort Study (STCS) is a large, nation-
wide, well-documented prospective cohort including all SOT re-
cipients followed at 6 Swiss university transplantation centers
(Basel, Bern, Geneva, Lausanne, St. Gallen, and Zurich) since
May 2008 [8]. Patient data were systematically collected on stan-
dardized case report forms at enrollment, 6 months after trans-
plantation, and every 12 months after transplantation.
Infectious complications were systematically evaluated by
an infectious diseases specialist on the basis of clinical, histo-
logical, radiological, and mycological evidence and reported
on a separate case report form. Medical records for patients
reported to have fungal colonization or IMI were revised by
an independent investigator (T. L.) [9]. Proven or probable
IMI was deﬁned on the basis of standardized European Orga-
nisation for Research and Treatment of Cancer/Mycoses Study
Group guidelines and deﬁnitions [10] and adapted Interna-
tional Society for Heart and Lung Transplantation guidelines
and deﬁnitions unique for lung transplant recipients, such as
anastomotic bronchial infections or tracheobronchitis [11].
Colonization was deﬁned by microscopic or culture detection
of a mold from a specimen from a nonsterile site, including
sputum, bronchoalveolar lavage, bronchial brush, sinus aspi-
rate, or urine samples, in the absence of clinical signs/symptoms
for infection. Patients who received a diagnosis of mold
colonization and/or IMI before transplantation and/or who
previously received an organ transplant were excluded. CMV
infection was classiﬁed as asymptomatic replication, viral
syndrome, or probable and proven disease as previously
reported [12].
Ethics Statement
All patients provided a written informed consent for participa-
tion in the STCS (including genetic analyses). The protocol was
approved by the independent ethics committees of each Swiss
participating center (University Hospital of Lausanne; Univer-
sity Hospitals of Geneva; University Hospital Zürich; Cantonal
Hospital St. Gallen; Inselspital, Bern University Hospital; Clini-
ca Luganese, Lugano; and University Hospital of Basel).
Fresh venous blood specimens were collected for functional
studies from healthy volunteers who provided a written in-
formed consent. The protocol was approved by the local ethics
committee (Radboud University Nijmegen Medical Center, the
Netherlands).
Peripheral Blood Mononuclear Cell (PBMC) Isolation and In
Vitro–Stimulation Assays
PBMCs were isolated using Ficoll-Paque Plus density gradient
centrifugation (GE Healthcare, Zeist, the Netherlands) as de-
scribed previously [13]. Cells were subsequently stimulated
with 1 × 107 live or heat-inactivated Aspergillus fumigatus co-
nidia per milliliter for 24 hours or 7 days, respectively. After-
ward, concentrations of the cytokines tumor necrosis factor α
(TNF-α), interleukin 1β (IL-1β), interleukin 1 receptor antago-
nist (IL-1Ra), interleukin 17 (IL-17), interleukin 2 (IL-22; all
from R&D Systems, Minneapolis Minnesota) and interferon γ
(IFN-γ; Sanquin, Amsterdam, the Netherlands) were measured
in cell supernatants by enzyme-linked immunosorbent assays
according to the manufacturer’s protocol.
Genotyping
A total of 24 single-nucleotide polymorphisms (SNPs) in 21
genes were selected from the literature by performing a PubMed
search until June 2012, using the keywords “candidemia”, “can-
didiasis”, “aspergillosis”, and “SNP” and by searching previous
reviews on fungal immunogenetics [6, 7]. Blood samples were
obtained from all SOT recipients at the time of transplantation.
Genomic DNA was extracted from blood specimens obtained
from patients or healthy volunteers and stored in ethylenedi-
aminetetraacetic acid–containing tubes, using the Gentra Pure-
gene Blood Kit (Qiagen). Genotyping was performed using
a customized GoldenGate Genotyping Assay on Veracode
platform (Illumina, San Diego, California), unless otherwise in-
dicated. Results were analyzed on a BeadXpress Reader accord-
ing to standard protocols and quality controls. Additional SNPs
were genotyped using the Competitive Allele-Speciﬁc PCR sys-
tem (LGC Genomics, Herts, United Kingdom). For functional
studies, genotyping of the IL1B rs16944 and IL1RN rs419598
variants was performed on the ABI-Prism StepOne thermo-
cycler (Applied Biosystems), using predesigned SNP assays.
Statistical Analysis
Statistical analyses were performed in Stata13 (StataCorp, Col-
lege Station, Texas), unless otherwise indicated. The cumulative
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incidence of mold colonization and IMI by genetic variants at
36 months after the ﬁrst transplantation was assessed by the
log-rank test, with censoring at the date of the last follow-up
visit or death. Associated variants were selected on the basis
of log-rank test results and were further tested by univariate
and multivariate Cox models. To estimate the independent con-
tribution of each polymorphism to the end points, demographic
and clinical factors previously associated with mold coloniza-
tion and/or IMI, as described elsewhere [5, 9], were entered
into multivariate stepwise regression models (P < .2), together
with relevant genetic polymorphisms. Haplotypes were inferred
using PHASE 2.1 (University of Washington, Seattle). The power
calculation for Cox proportional hazard regression analysis was
done using an R implementation of the power and sample size
calculation for survival analysis of epidemiological studies
(powerSurvEpi R package 0.0.6) [14]. The effect of the presence
of SNPs on the Aspergillus-induced cytokine levels was deter-
mined by the Mann–Whitney U test. The data are presented
as mean values ± standard error of the mean and were analyzed
using GraphPad Prism v5.0 (San Diego, California).
RESULTS
Cohort Study
The study included 1101 white patients who received a SOT
(670 received a kidney transplant, 190 received a liver trans-
plant, 102 received a lung transplant, 79 received a heart trans-
plant, 15 received an islet/pancreas transplant, and 45 received
combined organ transplants) between May 2008 and December
2011 (Table 1). Mold colonization and IMI were diagnosed in
45 patients (4.1%) and 26 patients (2.4%), respectively. Most
IMIs (17 [75%]) occurred >3 months after transplantation.
The most frequent causative organism of IMI was Aspergillus
species (21 IMIs [81%]); only 5 IMIs were due to other fungi,
including Fusarium species (2 IMIs), Alternaria species (1
IMI), Zygomycetes species (1 IMI), and mixed pathogens (Zy-
gomycetes and Fusarium species [1 IMI]). Factors signiﬁcantly
associated with IMI were identiﬁed and described elsewhere [9]
and included in the multivariate analysis.
Genetic Risk Factors for Mold Colonization and IMI in SOT
Recipients
The minor allele frequency of the 24 SNPs are shown in Table 2.
Three SNPs that deviated from Hardy–Weinberg equilibrium
were excluded from the analyses. The power to detect mold col-
onization and IMI was calculated for each SNP (Table 4).
To assess the risk of fungal disease according to the different
SNPs, we estimated their associations with colonization and in-
fection during the ﬁrst 36 months after transplantation
(Table 2). Mold colonization and IMI were both associated
with SNPs in 3 different genes, including the genes encoding
IL-1β (IL1B; rs16944; TT vs CT or CC; P = .001 and P = .00005,
Table 1. Demographic Characteristic of Solid-Organ Transplant
(SOT) Recipients
Variable Value
Age, y, median (IQR)
Recipient 54 (19)
Donora 53 (22)
Sex
Recipient
Male 730 (66)
Female 371 (34)
Donorb
Male 573 (52)
Female 523 (48)
White race 1101 (100)
Duration of cold ischemia, d, median (IQR) 5.6 (7.3)
Transplanted organ
Kidney 670 (61)
Liver 190 (17)
Lung 102 (9)
Heart 79 (7)
Pancreas and islets 15 (1)
Mixedc 45 (4)
Donor typed
Deceased 801 (73)
Living related/unrelated 299 (27)
Rejection typee
Acute cellular rejection 342 (31)
Acute humoral rejection 35 (3)
CMV characteristic
Infection 279 (25)
Disease 61 (6)
Serostatusf
D+ R+ 350 (33)
D− R+ 256 (24)
D− R− 245 (24)
D+ R− 218 (20)
Induction therapyg
BAS 641 (61)
Anti-thymocyte globulin ± BAS 188 (18)
None 225 (21)
Maintenance regimenth
Calcineurin inhibitors 817 (92)
Corticosteroids 910 (83)
MMF 721 (81)
AZA 31 (3)
mTOR inhibitors 54 (6)
Anti-IMI prophylaxis (wks 1–4) 74 (7)
Data are no. (%) of 1101 SOT recipients, unless otherwise indicated.
Abbreviations: AZA, azathioprine; BAS, basiliximab; CMV, cytomegalovirus; IMI,
invasive mold infection; IQR, interquartile range; MMF, mycophenolate mofetil;
mTOR, mammalian target of rapamycin.
a Data were missing for 104 patients.
b Data were missing for 5 patients.
c Including kidney and pancreas (n = 24), kidney and liver (n = 10), kidney and
kidney (n = 5), kidney and islets (n = 3), two kidneys and pancreas (n = 2),
kindey and lung (n = 1).
d Data were missing for 2 patients.
e Reported at any time of follow-up.
f Data were missing for 32 patients.
g Data were missing for 47 patients.
h Reported at month 12.
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respectively), β-defensin 1 (DEFB1; rs1800972; CC vs GG or
CG; P = .001 and P = .0002, respectively), and IL-1Ra (IL1RN;
rs419598; CC vs CT or TT; P = .01 and P = .02, respectively;
Figure 1). In addition, we observed a signiﬁcant association
between a SNP in the gene encoding surfactant-associated pro-
tein 2 (SFTPA2; rs17886395; GG vs CC or CG) and mold
colonization (P = .004) but not infection (P = .5). However,
the number of cases carrying this polymorphism was very
small (Supplementary Figure 4).
To determine whether the SNPs were independent risk fac-
tors for mold colonization and IMI, we used multivariate Cox
stepwise regression models, after adjustment for all relevant
covariates (Table 3). The ﬁnal model for colonization still
included IL1B rs16944 (hazard ratio [HR], 2.52; 95% conﬁdence
interval [CI], 1.18–5.36; P = .02), DEFB1 rs1800972 (HR, 6.11;
95% CI, 2.28–16.4; P = .0003), and IL1RN rs419598 (HR, 3.35;
95% CI, 1.31–8.58; P = .01). The ﬁnal model for IMI still includ-
ed IL1B rs16944 (HR, 4.29; 95% CI, 1.71–10.8; P = .002) and
DEFB1 rs1800972 (HR, 4.73; 95% CI, 1.46–15.3; P = .01) but
not IL1RN rs419598. Associations were stronger when the
SNPs were combined together (for IL1B rs16944 and DEFB1
rs1800972: HR, 4.94 [95% CI, 2.06–11.8; P = .003]; for IL1B
rs16944 and IL1RN rs419598: HR, 4.64 [95% CI, 1.92–11.2;
P = .0006]; Supplementary Figure 1). To account for a possible
confounding role of antifungal prophylaxis, the analyses were
repeated after removal of patients who received antimold
Table 2. Association Between Genetic Polymorphisms and Mold Colonization or Invasive Mold Infection (IMI) in Solid-Organ Transplant
(SOT) Recipients
Gene (nt, aa Change)a
Reference
SNP ID MAF HWE
P valueb
Mold Colonization
(n = 45)
IMI
(n = 26)
IL1B (−511 C/T) rs16944 0.33 0.160 .001c .00005d
DEFB1 (−44 C/G) rs1800972 0.18 1.000 .001c .0002e
IL1RN (2018T/C) rs419598 0.25 0.320 .01 .02
TLR9 (−1237 C/T) rs5743836 0.13 0.060 .2 .04
INFG (874 T/A) rs2069705 0.33 0.086 .05 .06
PLG (D472N) rs4252125 0.30 0.340 .4 .1
CD209 (−139 A/G) rs2287886 0.36 0.610 .2 .2
IL10 (−1082 A/G) rs1800896 0.44 0.220 .8 .2
TLR6 (S249P) rs5743810 0.35 0.180 .1 .4
TNF (−308 G/A) rs1800629 0.14 0.010 .2 .4
SFTPA2 (A91P) rs17886395 0.14 0.900 .004 .5
CXCL10 (1642G/C) rs3921 0.41 0.280 .6 .5
MBL (G54D) rs1800450 0.15 0.099 .8 .4
IL10 (−819 C/T) rs1800871 0.27 0.820 .8 .6
TLR1 (R80 T) rs5743611 0.07 0.500 .6 .7
TLR4 (D299G) rs4986790 0.05 0.540 .8 .8
IL1A (−889 C/T) rs1800587 0.29 0.620 .6 .8
MASP2 (D105G) rs72550870 0.02 0.150 .8 .8
CLEC7A (Y238X) rs16910526 0.08 0.340 .7 .8
TLR3 (L412F) rs3775291 0.29 1.000 .9 .9
IL23R (R381Q) rs11209026 0.07 0.811 .7 .7
Data are for 1101 SOT recipients, unless otherwise indicated.
Abbreviations: aa, amino acid; CD209, gene encoding CD209; CLEC7A, gene encoding C-type lectin domain 7; CXCL10, gene encoding CXC-chemokine ligand 10;
DEFB1, gene encoding β-defensin 1; HWE, Hardy-Weinberg equilibrium; ID, identification; INFG, gene encoding interferon γ; IL1A, gene encoding interleukin 1α;
IL1B, gene encoding interleukin 1β; IL1RN, gene encoding interleukin 1 receptor antagonist; IL10, gene encoding interleukin 10; IL23R, gene encoding interleukin 23
receptor; MAF, minor allele frequency; MASP2, gene encoding mannan-binding lectin serine peptidase 2; MBL, gene encoding mannose binding lectin; nt,
nucleotide; PLG, gene encoding plasminogen; SFTPA2, gene encoding surfactant protein A2; SNP, single-nucleotide polymorphism; TLR1, gene encoding Toll-
like receptor 1; TLR3, gene encoding Toll-like receptor 3; TLR4, gene encoding Toll-like receptor 4; TLR6, gene encoding Toll-like receptor 6; TLR9, gene
encoding Toll-like receptor 9; TNF, gene encoding tumor necrosis factor.
a Three SNPs that deviated from HWE (TLR1 rs5743618, IL4 rs2243250, and CARD9 rs10870077) were excluded from the analyses.
b By the log-rank test, recessive mode (patients homozygous for the rare alleles are compared to the other patients). Five patients who were colonized with mold
before transplantation, of whom 2 also developed IMI before transplantation, were removed from the analyses.
c Significant after Bonferroni correction for multiple testing (21 tests; P = .02).
d Significant after Bonferroni correction for multiple testing (21 tests; P = .001).
e Significant after Bonferroni correction for multiple testing (21 tests; P = .004).
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prophylaxis. The associations between the SNPs in IL1B,
DEFB1, and IL1RN were still signiﬁcant on repeat analysis
(not shown).
IL1B rs16944 and IL1RN rs419598 Risk Haplotype for Mold
Colonization and IMI
IL1B and IL1RN are located within an approximately 400 kb re-
gion on chromosome 2q13-21. We therefore analyzed whether
haplotypic combinations of IL1B rs16944 and IL1RN rs419598
SNPs further inﬂuenced mold colonization and IMI (Figure 2).
Carriage of the rs16944-rs419598 C-T haplotype was associated
with a decreased risk of both mold colonization and IMI (C-T
haplotype vs all others: HR, 0.34 [95% CI, .18–.63; P = .0007]
and 0.21 [95% CI, .10–.45; P = .00008], respectively). Converse-
ly, carriage of the T-C haplotype was associated with an in-
creased risk for both phenotypes (T-C haplotype vs all others:
Figure 1. Cumulative incidence of mold colonization (n = 45) and invasive mold infection (IMI; n = 26), according to polymorphisms in genes encoding
interleukin 1β (IL1B; rs16944; A and B, respectively), β-defensin 1 (DEFB1; rs1800972; C and D, respectively), and interleukin 1 receptor antagonist (IL1RN;
rs419598; E and F, respectively), in solid-organ transplant recipients. Patients with mold colonization or IMI before engraftment were excluded from the
analyses. P values were calculated by the log-rank test, recessive mode (patients homozygous for the rate alleles are compared to the other patients). For
the IL1B rs16944 and DEFB1 rs1800972 single-nucleotide polymorphisms, P values remained signiﬁcant after correction for multiple testing (21 tests; IL1B
rs16944, colonization P = .02, IMI P = .001; and DEFB1 rs1800972, colonization P = .02, IMI P = .004).
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Table 3. Independent Factors Associated With Mold Colonization and Invasive Mold Infection (IMI) in Solid-Organ Transplant Recipients
Variable
Mold Colonization (n = 42) IMI (n = 25)
HR (95% CI) P valuea HR (95% CI) P valuea
IL1B rs16944 (TT vs CC/CT)b 2.52 (1.18–5.36) .02 4.29 (1.71–10.8) .002c
DEFB1 rs1800972 (CC vs GG/GC)b 6.11 (2.28–16.4) .0003d 4.73 (1.46–15.3) .01
IL1RN rs419598 (CC vs TT/TC)b 3.35 (1.31–8.58) .01 2.50 (.75–8.29) .1
Lung or heart transplantation 11.5 (5.83–22.6) <.0001 3.12 (1.21–8.03) .02
MMF 0.32 (.16–.63) .001 0.14 (.06–.33) <.0001
Tacrolimus 0.52 (.27–1.03) .06 0.45 (.19–1.09) .1
Corticosteroids . . . . . . 3.03 (.67–13.7) .1
Acute/chronic rejection . . . . . . 2.35 (.94–5.83) .07
CMV infection/disease 1.83 (.89–3.72) .1 2.68 (1.11–6.50) .03
Recipient age (per year) 1.04 (1.01–1.06) .008 1.06 (1.02–1.10) .004
The total number of patients in the multivariate analysis (n = 1047) was slightly lower than in the univariate analysis (n = 1101), owing to missing covariates. Five
patients who were colonized with mold before transplantation, of whom 2 also developed IMI before transplantation, were removed from the analyses.
Abbreviations: CI, confidence interval; CMV, cytomegalovirus; DEFB1, gene encoding β-defensin 1; HR, hazard ratio; IL1B, gene encoding interleukin 1β; IL1RN,
gene encoding interleukin 1 receptor antagonist; MMF, mycophenolate mofetil.
a By Cox proportional multivariate analysis, with stepwise regression variable selection. The variables included in the initial model were recipient age and sex, CMV
infection or disease, mycophenolate mofetil, tacrolimus and corticosteroid treatment, acute/chronic rejection, and type of transplanted organ.
b Genetic associations are for recessive mode (patients homozygous for the rare alleles are compared to the other patients).
c Significant after Bonferroni correction for multiple testing (21 tests; P = .04).
d Significant after Bonferroni correction for multiple testing (21 tests; P = .006).
Figure 2. Cumulative incidence of mold colonization (A and B) and invasive mold infection (IMI; C and D) according to rs16944-rs419598 C-T (A and C)
or T-C (B and D) haplotypes of polymorphisms in the genes encoding interleukin 1β (IL-1β) and interleukin 1 receptor antagonist (IL1-Ra) among solid-organ
transplant recipients. P values were calculated by the log-rank test by using the dominant mode of inheritance (patients carrying 1 or 2 copies of each
haplotype are compared to the other patients). Patients with mold colonization or IMI before engraftment were excluded from the analyses.
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HR, 1.83 [95% CI, 1.02–3.29; P = .04] and 2.09 [95% CI,
.97–4.50; P = .06], respectively).
Effect of IL1B rs16944 and IL1RN rs419598 SNPs on Aspergillus-
Induced Cytokine Release
To determine whether the SNPs associated with IMI and colo-
nization had measurable biological effects, we analyzed the pro-
duction of different cytokines that are involved in antifungal
host defense, including IL-1β, IL-1Ra, TNF-α, IL-17, IL-22,
and IFN-γ in PBMCs from 73 healthy volunteers, after stimu-
lation with live or heat-inactivated A. fumigatus conidia (Fig-
ure 3). PBMCs from volunteers carrying the IL1B rs16944 TT
genotype produced lower amounts of IL-1β (P = .01), TNF-α
(P = .03), and IL-22 (P = .03) after stimulation with A. fumiga-
tus, compared with PBMCs from volunteers carrying the TC
and CC genotypes. However, the production of IL-1Ra, IL-17,
and IFN-γ was not signiﬁcantly inﬂuenced by IL1B rs16944.
PBMCs from volunteers carrying the IL1RN rs419598 CC geno-
type produced lower amounts of IL-1β (P = .03) and TNF-α
(P = .04) after stimulation with A. fumigatus, compared with
PBMCs from volunteers carrying the TC and TT genotypes.
However, the production of IL-1Ra itself, as well as IL-22, IL-
17 and IFN-γ, was not inﬂuenced by IL1RN rs419598.
DISCUSSION
While a number of investigators have reported associations be-
tween genetic polymorphisms and susceptibility to invasive as-
pergillosis among patients with onco-hematological conditions
[6, 7], the role of such polymorphisms has not been studied
among SOT recipients. We are the ﬁrst to report an association
between polymorphisms in IL1B, its antagonist IL1RN, and
DEFB1 on the susceptibility to IMI in this population.
The IL1B gene encodes the cytokine IL-1β, which is essential
in host defense against Aspergillus infection [15]. IL-1β is a potent
proinﬂammatory cytokine that recruits neutrophils, which are
crucial for clearing Aspergillus [16], to the lungs during infection.
Resting Aspergillus conidia in the respiratory epithelium are de-
tected by alveolar macrophages and/or dendritic cells (DCs).
These cells express a wide variety of pattern-recognition receptors
(PRRs) [17] that detect molecular patterns from the fungal cell
wall (eg, o-linked mannan, galactomannan, and β-[1–3]-glucan)
[7].Whereas macrophages produce TNF-α and IL-1β upon rec-
ognizing Aspergillus, resulting in the recruitment of neutrophils
and monocytes, activated DCs will migrate to lymph nodes to in-
duce protective T-helper cell activity. IL-1β induces T-helper type
17 (Th17) responses that are characterized by the production of
IL-17, leading to increased recruitment of neutrophils. Addition-
ally, the activated T-helper cells induce IL-22 responses that will
stimulate production of defensins by epithelial cells [7, 13]. Thus,
IL-1β is a key player in the induction of protective innate and
adaptive anti-Aspergillus host defense.
Because of its potent inﬂammatory capacity, the IL-1β re-
sponse must be tightly controlled. This is underlined by the ob-
servation that patients with a mutation in IL-1Ra have severe
inﬂammation of the skin and bones because of uncontrolled
neutrophil inﬂux and increased Th17 responses [18]. Moreover
IL-1Ra knockout mice were shown to be fully protected from
developing invasive aspergillosis [19]. Importantly, galactosa-
minogalactan, an antiinﬂammatory cell wall component of A.
fumigatus, was able to induce IL-1Ra in vivo and consequently
suppress the IL-1β pathway, leading to increased susceptibility
to invasive aspergillosis [19]. IL-1β binds to the IL-1 receptor,
and this results in the recruitment of a second receptor (IL-
1RacP) [20] that activates signaling transduction pathways,
thereby exerting potent inﬂammatory activities. IL-1Ra also
binds to the IL-1 receptor but prevents recruitment of the sec-
ond receptor and thus does not activate signal transduction
pathways [20]. Therefore, the bioactivity of IL-1β is controlled
by IL-1Ra [21].
The polymorphisms associated with mold colonization and
IMI in this study are located within the IL-1 cluster, located
in chromosome 2, encompassing both IL1B and IL1RN. We
found that the minor alleles of rs16944 and rs1143627 within
IL1B were associated with an increased risk of mold coloniza-
tion and IMI in SOT recipients. Consistent with our observa-
tion, the minor allele of rs16944 tended to be associated with
an increased risk of invasive pulmonary aspergillosis in a
case-control study of 110 neutropenic patients with hematolog-
ical malignancies [22].The minor alleles of these SNPs were also
associated with susceptibility to different bacterial and viral in-
fections. Two studies showed an association between rs16944
and/or rs1143627 and mortality due to meningococcal disease
[23]. Studies among Chinese patients also showed an asso-
ciation between both SNPs and susceptibility to sepsis after
major trauma [24] and 2009 pandemic inﬂuenza A(H1N1)
virus [25].
It has been previously shown that rs16944, located at position
−511, which corresponds to a putative AP-2 binding site, and
rs1143627, located at position −31 within the TATA box, are
functional polymorphisms that could be responsible for alter-
ation of promoter activity and thus be able to modulate expres-
sion and secretion of IL-1β in vitro [26]. In our study, PBMCs
from individuals carrying 2 copies of a rare allele of IL1B
rs16944 had diminished IL-1β release upon Aspergillus stimula-
tion. In line with our data, human monocytes from individuals
carrying the minor allele of rs1143627 had moderated transcrip-
tional activity of IL1B promoter in response to lipopolysaccha-
ride (LPS) [26]. Moreover, carriers of minor alleles of rs16944
or rs1143627 had signiﬁcantly lower IL-1β levels in LPS-
induced PBMCs [27]. However, other studies have reported
that the minor allele of rs16944 was correlated with increased
transcriptional activity of the promoter in vitro upon LPS stim-
ulation and high IL-1β secretion [28, 29]. There is no clear
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Figure 3. Levels of Aspergillus-induced tumor necrosis factor α (TNF-α), interleukin 1β (IL-1β), interleukin 1 receptor antagonist (IL-1Ra), interleukin 17
(IL-17), interleukin 22 (IL-22), and interferon γ (IFN-γ) release by human peripheral blood mononuclear cells (PBMCs), depending on the presence or absence
of single-nucleotide polymorphisms (SNPs) in 2 copies of the genes encoding IL-1β (IL1B; rs16944; A) or IL-1Ra (IL1RN; rs419598; B). PBMCs from 73 healthy
volunteers with different IL1B rs16944 or IL1RN rs419598 genotypes were stimulated either with live Aspergillus fumigatus conidia for 24 hours (for TNF-α,
IL-1β, and IL-1Ra) or heat-inactivated A. fumigatus conidia for 7 days (for IL-17, IL-22, and IFN-γ). The cytokine levels were measured in cell culture
supernatants. Differences in the effects of SNPs on cytokine levels were calculated by the Mann–Whitney U test. The data are presented as mean ± stan-
dard error of the mean (SEM).
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explanation for these discrepant observations, but they may be
due, at least in part, to the use of different cells or tissues; the use
of different stimuli, stimulating concentrations, or durations;
and/or the failure to account for other, so far unknown, regulat-
ing factors. We found that the IL1B rs16944 polymorphism was
not only associated with less IL-1β production, but also with re-
duced TNF-α production in response to Aspergillus. TNF-α is
another essential cytokine in antifungal host defense, and anti-
TNF treatment has previously been associated with invasive as-
pergillosis [24, 30].
The IL1RN rs419598 SNP, which is in strong linkage dis-
equilibrium with the IL1RN variable number tandem repeat
(VNTR) sequence, has also been associated with mold coloni-
zation and IMI [31]. Consistent with this ﬁnding, the minor
allele of rs419598 was previously associated with severity of
meningococcal disease and genital human papillomavirus
clearance [23, 32]. To our knowledge, the functional role of
rs419598 has not been explored so far. In the present study,
the minor allele of rs419598 did not inﬂuence IL-1Ra produc-
tion in PBMCs from volunteers stimulated with A. fumigatus.
However, rs419598 carriers had signiﬁcantly lower levels of IL-
1β and TNF-α. This is consistent with a previous study, in
which VNTR*2 was associated with decreased IL-1β produc-
tion in the gastric mucosa, as well as in PBMCs stimulated
with LPS [28, 33]. Together, these data suggest that IL1RN par-
ticipates in the regulation of Aspergillus-mediated cytokine
production and that IL1RN polymorphisms may reduce the
ability to clear the pathogen.
Table 4. Power to Detect an Association Between Genetic Polymorphisms and Mold Colonization or Invasive Mold Infection (IMI) in
Solid-Organ Transplant Recipients
Gene (nt, aa Change)a
Reference
SNP ID MAF
Colonization (Frequency 4.1%) IMI (Frequency 2.4%)
Power to Detect
Colonization Observed Value Power to Detect IMI Observed Value
HR, 3 HR, 4 HR, 5 HR P valueb HR, 3 HR, 4 HR, 5 HR P valueb
IL10 (−1082 A/G) rs1800896 0.44 0.62 0.90 0.98 0.89 .8 0.29 0.57 0.77 0.34 .1
CXCL10 (1642G/C) rs3921 0.41 0.61 0.89 0.98 0.79 .6 0.28 0.55 0.76 0.67 .5
CD209 (−139 A/G) rs2287886 0.36 0.58 0.87 0.97 0.50 .2 0.26 0.52 0.72 0.28 .2
TLR6 (S249P) rs5743810 0.35 0.57 0.86 0.97 1.78 .1 0.25 0.51 0.71 1.47 .4
IL1B (−511 C/T)c rs16944 0.33 0.55 0.85 0.96 2.98 .002 0.24 0.49 0.70 4.67 .0002
INFG (874 T/A) rs2069705 0.33 0.55 0.85 0.96 0.17 .08 0.24 0.49 0.70 0.00 1.0
PLG (D472N) rs4252125 0.30 0.51 0.82 0.95 1.45 .4 0.22 0.46 0.66 2.24 .1
IL1A (−889 C/T) rs1800587 0.29 0.50 0.81 0.94 1.24 .6 0.21 0.45 0.65 0.81 .8
TLR3 (L412F) rs3775291 0.29 0.50 0.81 0.94 1.10 .8 0.21 0.45 0.65 0.94 .9
IL10 (−819 C/T) rs1800871 0.27 0.47 0.78 0.93 1.02 1.0 0.20 0.42 0.62 0.56 .6
IL1RN (2018T/C) rs419598 0.25 0.44 0.75 0.91 2.84 .02 0.18 0.39 0.58 3.36 .03
DEFB1 (−44 C/G) rs1800972 0.18 0.30 0.59 0.79 4.08 .003 0.12 0.27 0.42 5.91 .001
MBL (G54D) rs1800450 0.15 0.24 0.49 0.70 0.80 .8 0.09 0.21 0.34 0.00 1.0
SFTPA2 (A91P) rs17886395 0.14 0.22 0.45 0.66 4.79 .009d 0.08 0.19 0.31 0.00 1.0
TNF (−308 G/A) rs1800629 0.14 0.22 0.45 0.66 0.00 1.0 0.08 0.19 0.31 0.00 1.0
TLR9 (−1237 C/T) rs5743836 0.13 0.19 0.41 0.61 2.27 .3 0.07 0.17 0.28 4.13 .054
CLEC7A (Y238X) rs16910526 0.08 0.09 0.21 0.34 0.00 1.0 0.03 0.08 0.13 0.00 1.0
TLR1 (R80T) rs5743611 0.07 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
IL23R (R381Q) rs11209026 0.07 0.07 0.17 0.28 0.00 1.0 0.03 0.06 0.11 0.00 1.0
TLR4 (D299G) rs4986790 0.05 0.04 0.09 0.16 0.00 1.0 0.02 0.04 0.06 0.00 1.0
MASP2 (D105G) rs72550870 0.02 0.01 0.02 0.03 0.00 1.0 0.005 0.009 0.01 0.00 1.0
Abbreviations: aa, amino acid; CD209, gene encoding CD209; CLEC7A, gene encoding C-type lectin domain 7; CXCL10, gene encoding CXC-chemokine ligand 10;
DEFB1, gene encoding β-defensin 1; HR, hazard ratio; HWE, Hardy-Weinberg equilibrium; ID, identification; INFG, gene encoding interferon γ; IL1A, gene encoding
interleukin 1α; IL1B, gene encoding interleukin 1β; IL1RN, gene encoding interleukin 1 receptor antagonist; IL10, gene encoding interleukin 10; IL23R, gene
encoding interleukin 23 receptor; MAF, minor allele frequency; MASP2, gene encoding mannan-binding lectin serine peptidase 2; MBL, gene encoding
mannose binding lectin; nt, nucleotide; PLG, gene encoding plasminogen; SFTPA2, gene encoding surfactant protein A2; SNP, single-nucleotide polymorphism;
TLR1, gene encoding Toll-like receptor 1; TLR3, gene encoding Toll-like receptor 3; TLR4, gene encoding Toll-like receptor 4; TLR6, gene encoding Toll-like
receptor 6; TLR9, gene encoding Toll-like receptor 9; TNF, gene encoding tumor necrosis factor.
a Three SNPs that deviated from HWE (TLR1 rs5743618, IL4 rs2243250, and CARD9 rs10870077) were excluded from the analyses.
b By Cox regression, recessive mode (patients homozygous for the rare alleles are compared to other patients).
c In almost complete linkage disequilibrium (R2 = 0.99) with the IL1B −31 T/C rs1143627.
d P = .01 for the additive mode (HR, 1.91; 95% confidence interval, 1.15–3.17).
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DEFB1 encodes human β-defensin 1, a member of the defen-
sin family. Defensins are encoded by a polymorphic gene cluster
located within a 450-kb region on chromosome 8p23 [34]. They
exert antimicrobial activity against a broad spectrum of patho-
gens; they also exert chemotactic activity on immune cells and
are able to induce cytokine production [35, 36]. β-defensin 1 is
constitutively expressed in lung epithelial cells and was shown
to exert antimicrobial properties against Candida albicans [37].
To our knowledge, the antimicrobial properties of this β-defen-
sin against other fungal pathogens have not been investigated.
The minor allele of the rs1800972 SNP in DEFB1 was associ-
ated with an increased risk of mold colonization and IMI in
SOT recipients. In line with our ﬁndings, the same allele was
previously associated with higher-level oral Candida carriage
among diabetic and nondiabetic patients [38]. The rs1800972
SNP is located at position −44 from the 5′ untranslated region
ofDEFB1 and was predicted to alter a putative transcription fac-
tor binding site to this region of the gene [39, 40]. The minor
allele of rs1800972 has been previously associated with lower
β-defensin 1 expression in the skin with increased nasal carriage
of Staphylococcus aureus [41]. This allele may also decrease the
expression of β-defensin 1 in the respiratory epithelium, with
reduced ability to clear opportunistic pathogens such as mold
under certain immunosuppressive conditions. Interestingly,
the cytokine IL-22 is a potent inducer of defensins produced
by epithelial cells [42, 43]. The IL1B rs16944 SNP was associated
with a signiﬁcant reduction in Aspergillus-induced IL-22 pro-
duction in human PBMCs. Therefore, it can be proposed that
this SNP may increase susceptibility, not only because of the
low production of essential innate immune system cytokines
such as IL-1β and TNF-α, but also because of a reduced induction
of IL-22 that might result in defective induction of defensins.
SFTPA2 encodes pulmonary surfactant-associated protein 2
(SP-A2), a member of the collagen-containing soluble C-type
lectin receptors (collectins). SP-A2 was shown to play an impor-
tant role in host response to Aspergillus by its ability to bind A.
fumigatus conidia and thus enhance phagocytosis by neutro-
phils and macrophages [44]. Polymorphisms in the collagen re-
gion of SFTPA2 (G1649C and/or A1660G) have been associated
with chronic cavitary pulmonary aspergillosis [45] and allergic
bronchopulmonary aspergillosis in asthmatic patients [46].
Here, we detected association between a G1649C polymor-
phism and mold colonization but not invasive mold infection
in SOT recipients. The lack of association with infection may
be due to insufﬁcient statistical power due to the relatively
small SNP allele frequency and sample size, as detailed in
Table 4.
By using 24 polymorphisms from 21 genes previously associ-
ated with susceptibility to fungal infections, we showed that
SNPs from 3 genes (IL1B, IL1RN, and DEFB1) were associated
with mold colonization or IMI in white SOT recipients. Mold
colonization may have been underestimated, as bronchoscopy
is not routinely performed, especially in nonthoracic SOT recip-
ients. Yet, the polymorphisms associated with colonization were
also associated with IMI, suggesting that these polymorphisms
inﬂuence both phenotypes, with a continuum from coloniza-
tion to invasive infection. We were not able to detect an associ-
ation with polymorphisms in other genes, such as TLR4 or
CLEC7A (which encodes dectin 1), that were previously report-
ed to be associated with invasive aspergillosis by several inves-
tigators [6, 7]. This may be due to several factors, such as the
inclusion of different study populations, fungal pathogens,
and/or less invasive forms of infections. Importantly, the num-
ber of patients with mold colonization and/or IMI was small,
leading to limited statistical power, especially for infrequent
SNPs, as detailed in Table 4. Larger studies and studies in patients
who are not white will be needed to replicate such associations.
We report an association between polymorphisms in 3 genes
and mold colonization and IMI in a nationwide cohort of SOT
recipients. Theses associations were found to be independent
from previously known risk factors, such as recipient age and
CMV coinfection [3]. The genes were formerly described as im-
portant components of immune defenses against fungal patho-
gens, and the associated polymorphisms were all shown to be
functionally relevant. Together, these ﬁndings may contribute
to a better understanding of the pathogenesis of IMI in SOT re-
cipients and help in individual risk stratiﬁcation in the future.
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